In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Hold rating on Bausch Health Companies Inc (NYSE: BHC), with a price target of $25. The company’s shares closed yesterday at $23.54.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.7% and a 45.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.
Bausch Health Companies Inc has an analyst consensus of Hold, with a price target consensus of $26, which is a 10.5% upside from current levels. In a report released yesterday, BMO Capital also maintained a Hold rating on the stock with a $24 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.79 and a one-year low of $10.94. Currently, Bausch Health Companies Inc has an average volume of 6.62M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
